Related Experiment Video
Updated: Aug 25, 2025
Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes
Published on: February 14, 2025
L007-0069 kills Staphylococcus aureus in high resistant phenotypes
She Pengfei1, Liu Yaqian1, Xu Lanlan1
1Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, China.
Abstract:
Staphylococcus aureus, a common gram-positive pathogenic bacterium, is a main cause of hospital infection. The prevalence rate of methicillin-resistant S. aureus (MRSA) has made its treatment difficult in recent decades. Moreover, S. aureus in the highly tolerant format of biofilm or persister often renders infections refractory. Thus, developing new active compounds against resistant S. aureus is urgently needed. In this study, by a high-throughput screening assay, we identified a small molecule, L007-0069, that exhibited strong and effective bactericidal activity against S. aureus and its high resistance patterns, such as biofilms and persisters, with a low probability of inducing resistance. By molecular dynamics and fluorescent probe analysis, mechanistic studies revealed that the bactericidal activity of L007-0069 was mainly mediated by membrane disruption and metabolic disorder induction. Furthermore, L007-0069 showed effective anti-MRSA effects in vivo in both a wound infection model and a peritonitis-sepsis model, with no detectable toxicity observed at the therapeutic dosage. In conclusion, L007-0069 has the potential to become an alternative for the treatment of highly resistant S. aureus-related infections.
Insights
A new compound, L007-0069, effectively kills drug-resistant Staphylococcus aureus, including biofilms and persisters. This compound shows promise for treating difficult infections with low resistance development potential.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Staphylococcus aureus is a major cause of hospital infections.
- Methicillin-resistant S. aureus (MRSA) infections are difficult to treat.
- Biofilm and persister forms of S. aureus are highly tolerant to antibiotics.
Purpose of the Study:
- To identify novel compounds effective against resistant S. aureus.
- To investigate the mechanism of action of identified compounds.
- To evaluate the in vivo efficacy and safety of promising candidates.
Main Methods:
- High-throughput screening assay to identify active compounds.
- Molecular dynamics and fluorescent probe analysis for mechanistic studies.
- In vivo efficacy testing in wound infection and peritonitis-sepsis models.
Main Results:
- L007-0069 demonstrated potent bactericidal activity against S. aureus, including biofilms and persisters.
- Mechanistic studies indicated membrane disruption and metabolic disorder induction by L007-0069.
- L007-0069 showed significant anti-MRSA effects in vivo with no observed toxicity at therapeutic doses.
Conclusions:
- L007-0069 is a promising small molecule for treating S. aureus infections.
- Its novel mechanism of action targets membrane integrity and metabolic pathways.
- L007-0069 represents a potential alternative therapeutic agent for highly resistant S. aureus infections.
Related Concept Videos
01:30Development of Antibiotic Resistance
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:28Gene Regulation in Microbial Communities: Quorum Sensing
00:57Antibiotic Selection